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peptides, can predict over a 5-year time span mildly impaired diastolic LV function as assessed by echocardiography. In 645
white Flemish (50.5% women; 50.9 years [mean]), we measured HF1 by capillary electrophoresis coupled with mass spec-
trometry in 2005–2010. We measured early (E) and late (A) peak velocities of the transmitral blood flow and early (e’) and
late (a’) mitral annular peak velocities and their ratios in 2009–2013. In multivariable-adjusted analyses, per 1-standard
deviation increment in HF1, e’ was 0.193 cm/s lower (95% confidence interval: 0.352 to 0.033; P ¼ .018) and E/e’ 0.174
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439Z.-Y. Zhang et al. / Journal of the American Society of Hypertension 12(6) (2018) 438–447in 69 patients (38.5%) or an elevated filling pressure in the presence of a normal (74 [43.8%]) or low (36 [20.1%]) age-specific E/A
ratio. For a 1-standard deviation increment inHF1, the adjusted odds ratiowas 1.37 (confidence interval, 1.07–1.76;P¼ .013). The
integrated discrimination (þ1.14%) and net reclassification (þ31.7%) improvement of the optimized HF1 threshold (0.350) in
discriminating normal from abnormal diastolic LV function at follow-up over and beyond other risk factors was significant
(P  .024). In conclusion, HF1 may allow screening for LVDD over a 5-year horizon in asymptomatic people. J Am Soc
Hypertens 2018;12(6):438–447.  2018 The Authors. Published by Elsevier Inc. on behalf of American Heart Association.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diastolic heart failure (DHF) represents half of all heart
failure cases1 and has a 30%death ratewithin 1 year of the first
hospital admission.2 Subclinical left ventricular (LV) diastolic
dysfunction (LVDD) has 25% prevalence in the general pop-
ulation.3,4 Hypertension, obesity, old age, and insulin resis-
tance are among the major risk factors.3,4 LVDD is an
insidious condition evolving to DHF.5 Screening for LVDD
at the point of entry in health care is extremely challenging
because it requires awareness of predisposing risk factors,
clinical interpretation of vague symptoms and signs, and LV
imaging demonstrating functional or structural LV changes.
The observation that natriuretic peptide levels in LVDD pa-
tients are often within normal limits3,4,6 complicates the mat-
ters further and justifies the quest for novel biomarkers specific
for LVDD at an early stage long before it progresses to DHF.
Capillary electrophoresis coupled with high-resolution
mass spectrometry (CE-MS) enables detection of over 5000
distinct peptides in urine samples.7,8 We previously identified
a multidimensional urinary classifier, HF1, mainly consisting
of dysregulated collagen fragments,9–11 which in case-control
studies9 and in the general population10,11 was reproducibly
associated with subclinical LVDD. In patients progressing
fromLVDD toDHF, the LVwall undergoes fibrosis character-
ized by increased interstitial deposition12 and cross-linking of
collagen I at the detriment of collagen III.13,14 We hypothe-
sized that urinary markers of collagen turnover, and circu-
lating serum markers of collagen degradation might predict
LVDD3,4 over and beyond known risk factors andmight there-
fore represent easily applicable screening tools in primary
care. We tested our hypothesis in participants enrolled in the
Flemish Study on Environment, Genes and Health Outcomes
(FLEMENGHO9–11), in whom we related the echocardio-
graphically assessed diastolic LV function (2009–2013) to
HF1, and the serum markers of collagen degradation
measured approximately 5 years earlier (2005–2010).MethodsStudy ParticipantsFLEMENGHO is a family-based population study,15,16
which complies with the Helsinki declaration17 andreceived ethical approval from the Ethics Committee of
the University Hospitals Leuven (approval number
B32220083510). For the current analysis, we selected 655
people, whose urinary proteome had been measured in
2005–2010 (baseline) and who had undergone echocardiog-
raphy in 2009–2013 (follow-up). The participation rate at
echocardiography was 80.0%. We excluded 10 participants,
whose diastolic LV function at follow-up could not be reli-
ably assessed, because of atrial fibrillation (N ¼ 6) or paced
heart rhythm (N ¼ 4). Thus, the number of participants sta-
tistically analyzed totaled 645.Clinical MeasurementsBody mass index (BMI) was weight in kilogram divided
by height in meters squared. Waist circumference was
determined using a measuring tape. Abdominal obesity
was a waist circumference of 88 cm in women and
102 cm in men.18 Blood pressure was the average of
five consecutive auscultatory readings. Hypertension was
a blood pressure of 140 mm Hg systolic or 90 mm
Hg diastolic or use of antihypertensive drugs. Estimated
glomerular filtration rate (eGFR) was derived from serum
creatinine (Crt) by the chronic kidney disease epidemiology
collaboration equation.19 Diabetes mellitus was a self-
reported diagnosis, a fasting plasma glucose
(Glyc) 7 mmol/L, or use of antidiabetic agents.20 Using
validate questionnaires21 and published tables,22 we
computed the energy spent in physical activity from body
weight, time devoted to work, walking, sports and leisure
time activities, and type of physical activity.EchocardiographyDetailed information on the acquisition and offline anal-
ysis of the echocardiographic images is available in previ-
ous publications.9,10 In short, echocardiographic
measurements, obtained with a Vivid7 Pro device (GE
Vingmed, Horten, Norway) interfaced with a 2.5–3.5-
MHz phased-array probe, were averaged over three heart
cycles. Diastolic LV function was assessed by the EchoPac
software, version 4.0.4 (GE Vingmed, Horten, Norway). In
keeping with guidelines,23 we determined peak early (E)
and late (A) diastolic velocities of the transmitral blood
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late (a’) mitral annular movement by tissue Doppler imag-
ing with velocities averaged over four acquisition sites
(septal, lateral, inferior, and posterior). Reproducibility
across the four tissue Doppler imaging sampling sides
ranged from 4.5% to 5.3% for e’ and from 4.0% to 4.5%
for a’. Patients with LVDD had an abnormally low age-
specific transmitral E/A ratio indicative of impaired relaxa-
tion or a mildly-to-moderately elevated LV filling pressure
(E/e’ > 8.5) with normal or decreased age-specific E/A ra-
tio. These age-specific criteria in a healthy reference sam-
ple drawn from FLEMENGHO3 were replicated in an
independent European population study.4BiomarkersParticipants collected 24-hour urine samples within 1
week of the echocardiographic examination at the field cen-
ter. For measurement of HF1 and microalbuminuria, ali-
quots (0.7 mL) were stored at 80C for 8 years
(median) and thawed immediately before analysis. Detailed
information about urine sample preparation, proteome anal-
ysis by CE-MS, data processing, and sequencing has been
published before.7,8 Peptides were combined into a single
summary variable, using the MosaCluster software, version
1.6.5. HF1 was originally derived in a case-control study
including participants with mild and moderate LVDD. It
consists of 85 peptides (Table S1), mainly collagen frag-
ments. HF1 is a robust9,10 urinary biomarker validated
before in case-control studies9 and in the general popula-
tion.10 HF1 is normally distributed, higher values being
associated with worse outcomes.10,24,25
At baseline (2005–2010), venous blood samples were
drawn after at least 8 hours of fasting. Carboxyterminal te-
lopeptide of collagen I (CITP) and tissue inhibitor of the
matrix metalloproteinase type I (TIMP-I) were measured
as circulating markers of collagen 1 degradation in 607 par-
ticipants (94.1%). CITP was quantified by a quantitative
enzyme immunoassay (Orion Diagnostica, Espoo, Finland)
and TIMP-I (GE Healthcare Life Sciences, Buckingham-
shire, UK) by sandwich enzyme-linked immunosorbent
assay.14 The detection limits were 0.3 mg/L for CITP (inter-
assay and intra-assay coefficients of variability, 13.1% and
10.0%) and 1.25 ng/mL for TIMP-I (12.8% and 2.6%).14 In
591 participants (91.6%), N-terminal pro b-type natriuretic
peptide (NT-proBNP) was also measured in plasma at base-
line by a competitive enzyme immunoassay for research
use (Biomedica Gruppe, Vienna, Austria).Statistical AnalysisFor database management and statistical analysis, we
used the SAS system, version 9.4 (SAS Institute Inc.,
Cary, NC). Means were compared using the large-sample
z-test and proportions by Fisher’s exact test. We normalizedthe distributions of the energy spent in physical activity and
24-hour microalbuminuria by a logarithmic transformation.
Our statistical methods also included multivariable-
adjusted linear and logistic regression with as dependent
variables the echocardiographic indexes reflecting diastolic
LV function on a continuous or binary scale. We adjusted
for baseline covariables of physiological relevance, identi-
fied in previous analyses, including sex, age, BMI, systolic
and diastolic blood pressure, heart rate, serum Crt, fasting
blood Glyc, and treatment with inhibitors of the renin sys-
tem and b-blockers. In sensitivity analyses, we replaced
BMI by waist circumference and additionally accounted
for 24-microalbuminuria, energy spent in physical activ-
ity.21,22 We determined optimal discrimination limits for
HF1 by maximizing Youden’s index (the maximum of
sensitivity plus specificity minus 1). Finally, we assessed
the incremental value of the urinary biomarkers in discrim-
inating between normal and abnormal LV function, using
the integrated discrimination improvement (IDI) and the
net reclassification improvement (NRI).26ResultsBaseline Characteristics of ParticipantsOf 645 participants, 326 (50.5%) were women. Mean
values (standard deviation) were 50.9  14.7 years for
age, 26.5  4.4 kg/m2 for BMI, 103.5  8.9 cm for waist
circumference, and 128.8  16.8/79.8  9.3 mm Hg for
systolic/diastolic blood pressure. Of all participants, 268
(41.6%) had hypertension, of whom 160 (59.7%) were on
antihypertensive drug treatment; 18 (2.8%) had a history
of diabetes mellitus; and 30 (4.7%) reported previous coro-
nary heart disease. The antihypertensive drug classes used
at baseline were diuretics in 59 (9.2%), b-blockers in 100
(15.5%), inhibitors of the renin-angiotensin system in 51
(7.9%), and calcium-channel blockers in 26 (4.0%) partic-
ipants. Table 1 lists the characteristics of participants by
quartiles of the HF1 distribution. Age, BMI, waist circum-
ference, systolic pressure, the prevalence of hypertension,
the use of antihypertensive drugs, or being overweight,
plasma Glyc, serum Crt, and TIMP-I all increased
(P  .004) with higher HF1 category, whereas the opposite
was the case for eGFR (P < .0001). Across the HF1 quar-
tiles, there were no differences (P  .12) in the prevalence
of abdominal obesity, the energy spent in physical activity,
or 24-hour microalbuminuria.Continuous AnalysesMedian follow-up time was 4.8 years (interquartile
range, 4.4–5.1 years; 5th–95th percentile interval, 3.7–5.4
years). Table S2 shows that the left atrial volume index,
A, and a’ peak velocities, and the E/e’ ratio were greater
(P  .010) with higher baseline HF1 category, whereas
Table 1
Baseline characteristics of 645 participants by quartiles of the HF1 distribution
Characteristic Categories of the Urinary HF1 Biomarker P
Limits, Score <1.623 1.623 to 1.047 1.046 to 0.445 >0.445
Number of subjects (%)
All patients in category 162 161 161 161
Women 83 (51.2) 84 (52.2) 85 (52.8) 74 (46.0) .60
Smokers 40 (24.7) 33 (20.5) 22 (13.7) 26 (16.2) .057
Drinking alcohol 60 (37.0) 57 (35.4) 61 (37.9) 60 (37.3) .60
Hypertension 44 (27.2) 60 (37.3) 62 (38.5) 102 (63.4)x <.0001
Antihypertensive treatment 18 (11.1) 27 (16.8) 38 (23.6) 77 (47.8)x <.0001
Body mass index 25 kg/m2 81 (50.0) 95 (59.0) 99 (61.5) 125 (77.6) <.0001
Abdominal obesity 122 (75.3) 131 (81.4) 126 (78.3) 133 (82.6) .37
History of coronary heart
disease
3 (1.9) 10 (6.2)* 7 (4.4) 14 (8.7) .043
Diabetes mellitus 2 (1.2) 0 4 (2.5)* 12 (7.5)* .0003
Mean of characteristic
Age, y 44.0  14.0 49.9  14.2z 52.0  13.5 57.5  13.9z <.0001
Body mass index, kg/m2 25.3  3.7 26.2  3.7* 26.4  4.5 28.3  5.0z <.0001
Waist circumference, cm 101.7  7.8 102.9  7.4 103.1  9.9 106.2  10.3y <.0001
Energy spent in physical
activity, Kcal
1725 (1300–2108) 1788 (1400–2221) 1781 (1367–2207) 1809 (1411–2200) .60
Blood pressure
Systolic pressure, mm Hg 125.2  14.0 128.4  18.9 128.1  16.1 133.3  17.2y .0003
Diastolic pressure, mm Hg 78.6  8.8 79.6  9.9 80.1  9.2 81.0  9.4 .13
Heart rate, beats per minute 60.2  9.1 60.3  9.6 60.0  9.8 59.8  10.6 .97
Biochemical data
Total cholesterol, mmol/L 5.22  1.51 5.45  1.10 5.29  0.95 5.29  0.97 .36
Plasma glucose, mmol/L 4.83  0.52 4.83  0.43 4.92  0.66 5.10  1.23 .004
Serum creatinine, mmol/L 81.8  13.4 83.4  12.9 83.5  13.0 88.1  21.1* .002
eGFR, ml/min/1.73 m2 87.5  14.9 82.1  16.5y 80.6  13.8 75.8  16.3y <.0001
24-h microalbuminuria, mg 5.29 (3.89–6.59) 5.73 (3.79–7.10) 5.83 (4.39–7.35) 6.38 (4.30–7.91) .12
CITP, mg/L 5.44  1.62 5.30  1.80 5.63  2.00 5.82  2.56 .13
TIMP-I, ng/mL 603  154 670  192z 679  154 730  224* <.0001
NT-proBNP, pmol/L 212 (158–284) 199 (143–288) 217 (148–318) 202 (130–284) .51
eGFR, estimated glomerular filtration rate calculated according to the CKD-EPI formula; CITP, carboxyterminal telopeptide of collagen I;
TIMP-I, tissue inhibitor of the matrix metalloproteinase type I; NT-proBNP, N-terminal pro b-type natriuretic peptide; SD, standard deviation.
Abdominal obesity was a waist circumference of 88 cm in women and 102 cm in men. Blood pressure was the average of five consec-
utive auscultatory readings. Heart rate was determined after 15 minutes recumbent rest. Hypertension was a blood pressure of 140 mm Hg
systolic or 90 mm Hg diastolic, or use of antihypertensive drugs. CITP and TIMP-I were available in 149, 153, 155, and 150 participants of
the 1st, 2nd, 3rd, and 4th quartile, respectively (607 in total). NT-proBNP was measured in 144, 149, 150, and 148 participants of the 1st, 2nd,
3rd, and 4th quartile, respectively (591 in total). Means are arithmetic means (SD) or geometric means (interquartile range). P values denote
the significance of the differences in prevalence rates or means across quartiles of the HF1 distribution.
* Significance of the difference with the adjacent lower quartile: P  .05.
yP  .01.
zP  .001.
xP < .0001.
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velocities and the E/A and e’/a’ ratios. e’ (r ¼ 0.79;
Figure 1, panel A), E/e’ (r ¼ 0.54; Figure 1, panel B),
and HF1 (r ¼ 0.36) were strongly dependent on age
(P < .0001). Stepwise cumulative adjustment for the cova-
riables (Figure 1, panels C and D) weakened the associa-
tions of e’ and E/e’ at follow-up with baseline HF1,
baseline age having the biggest impact (Figure 1, panels
C and D). With all adjustments applied, per 1-standarddeviation increment in HF1, e’ was 0.193 cm/s lower
(95% confidence interval [CI], 0.352 to 0.033;
P ¼ .018) and E/e’ 0.174 units higher (CI, 0.005–0.342;
P ¼ .043).
The corresponding association sizes were 0.005 (CI,
0.159 to 0.148; P ¼ .94) for CITP and 0.042 (CI,
0.205 to 0.120; P ¼ .61) for TIMP-I. When in the sensi-
tivity analysis, we replaced BMI by waist circumference
and additionally adjusted for energy spent in physical
Figure 1. Simple correlations of e0 (A) and E/e0 (B) with age. In panels A and B, red and blue dots indicate women and men, respec-
tively. Full lines represent the regression slopes, and dotted lines represent the 95% confidence boundaries for the prediction of the mean
values (blue) and individual values (red) of e0 and E/e0 at any given age. Associations of e0 (C) and E/e0 (D) with HF1 weaken as co-
variables were stepwise introduced in the regression model but remained significant after full adjustment. The association sizes are ex-
pressed for a 1-standard deviation increment in HF1. The shaded area denotes the 95% confidence boundary of the parameter estimates.
The percentage of explained variance is plotted along the horizontal axis. Stepwise cumulative adjustment was implemented for sex,
age, BMI, SBP, DBP, heart rate (HR), serum creatinine (Crt), fasting blood glucose (Glyc), and treatment with inhibitors of the renin
system (RAS) and b-blockers (BB).
442 Z.-Y. Zhang et al. / Journal of the American Society of Hypertension 12(6) (2018) 438–447activity and 24-microalbuminuria, e’ was 0.215 cm/s
lower (CI, 0.377 to 0.053; P ¼ .009) and E/e’ 0.179
units higher (CI, 0.009–0.349; P ¼ .039). None of the other
echocardiographic variables (E, A, E/A, e’/a’) was associ-
ated with HF1, CITP, or TIMP-I.Categorical AnalysesNext, we analyzed the relative risk of LVDD in relation
to HF1. Of 645 participants, 179 (27.8%) had LVDD at
follow-up, based on impaired relaxation in 69 patients
(38.5%) or an elevated filling pressure in the presence of
a normal (74 [43.8%]) or low (36 [20.1%]) age-specific
E/A ratio. The probability of having LVDD curvilinearly
increased with age (model R2 ¼ 0.32; Figure 2, panel A).
Age strongly influenced the parameter estimates for the as-
sociation of the risk of LVDD with baseline HF1 (Figure 2,
panel B). In multivariable-adjusted analyses, per 1-standard
deviation increment, the odds ratios were 1.37 (CI, 1.07–
1.76; P ¼ .013) for HF1, 1.16 (CI, 0.91–1.49; P ¼ .13)
for CITP, and 1.26 (CI, 0.96–1.66; P ¼ .09) for TIMP-I.
For a doubling of NT-proBNP, the odds ratio was 1.16(CI, 0.87–1.55; P ¼ .30). HF1 in the presence of NT-
proBNP yielded an odds ratio of 1.39 (CI, 1.07–1.81;
P ¼ .013). When in the sensitivity analysis, we replaced
BMI by waist circumference and additionally adjusted for
energy spent in physical activity and 24-
microalbuminuria, the odds ratios were 1.41 (CI, 1.10–
1.82; P ¼ .0068) for HF1 and 1.43 (CI, 1.10–1.86;
P ¼ .0071) for HF1 in the presence of NT-proBNP.Added Diagnostic AccuracyFrom baseline to follow-up, HF1 increased from
1.00  0.90 to 0.86  0.90 (P ¼ .0004). At baseline,
the optimized HF1 threshold was 0.350. Among all par-
ticipants, sensitivity was 43.0%, and specificity was
86.1%. Of 469 participants with baseline HF1 <0.350,
90 (19.2%) progressed to  0.350 at follow-up.
Conversely, of 129 participants with baseline HF1 at
baseline  0.350, 62 (48.1%) reverted to a value
of < 0.350 at follow-up. When stratified by age (50
versus <50 years), BMI (25 versus <25 kg/m2) or hyper-
tension versus normotension, sensitivity, and specificity
Figure 2. The probability of having LVDD curvilinearly increased with age (A). rage and rage2 are the partial correlation coefficients for
the linear and squared terms of age and Page and Page2 the corresponding significance levels. R
2 is the coefficient of multiple determi-
nation. In panel A, red and blue dots indicate women and men, respectively. The full line represents the regression slope, and the dotted
lines represent the 95% confidence boundaries for the prediction of the mean probabilities (blue) and individual probabilities (red) of
LVDD at any given age. The odds of having LVDD in relation to HF1 weakened as covariables were stepwise introduced in the logistic
model but remained significant after full adjustment (B). Odds ratios are expressed for a 1-standard deviation increment in HF1. The
shaded area denotes the 95% confidence boundary of the parameter estimates. Stepwise cumulative were implemented for sex, age,
BMI, SBP, DBP, heart rate (HR), serum creatinine (Crt), fasting blood glucose (Glyc), and treatment with inhibitors of the renin system
(RAS) and b-blockers (BB).
Table 2
Classification parameters by HF1 at baseline
Groups Classification Parameters Using 0.350 as Optimized HF1 Threshold
Sensitivity
(%)
Specificity
(%)
Positive
Predictive
Value (%)
Negative
Predictive
Value (%)
Misclassification
Rate
Integrated
Discrimination
Improvement (%)
Net Reclassification
Improvement (%)
All participants
(N ¼ 645)
43.0 86.1 54.2 79.7 25.9 1.14 (0.15 to 2.13)* 31.7 (14.9 to 18.5)z
Age 50 y
(N ¼ 345)
45.9 81.4 67.3 64.3 34.8 1.66 (0.30 to 3.02)* 39.2 (19.3 to 59.1)x
Age <50 y
(N ¼ 300)
77.3 89.2 85.7 93.6 15.7 0.07 (0.40 to 0.54) 19.1 (21.5 to 59.7)
BMI 25 kg/m2
(N ¼ 400)
43.1 82.3 59.6 70.3 32.6 0.81 (0.09 to 1.71) 26.7 (7.31 to 46.1)y
BMI <25 kg/m2
(N ¼ 245)
57.1 90.4 36.4 92.5 15.0 3.75 (0.39 to 7.88) 48.6 (9.81 to 87.4)*
Hypertension
(N ¼ 268)
47.3 76.3 64.9 60.9 37.7 0.78 (0.29 to 1.85) 21.0 (2.44 to 44.4)
Normotension
(N ¼ 377)
68.0 90.2 66.7 89.7 17.5 2.77 (0.18 to 5.73) 44.4 (17.8 to 71.1)y
BMI, body mass index.
The basic reference models included as covariables sex, age, BMI, systolic and diastolic blood pressure, heart rate, serum creatinine,
fasting blood glucose, and treatment with inhibitors of the renin system and b-blockers. The integrated discrimination improvement
(IDI) is the difference between the discrimination slopes of basic models and basic models extended with HF1. The discrimination slope
is the difference in predicted probabilities (%) between cases and controls. Cases and controls are participants with and without LVDD,
respectively. The net reclassification improvement (NRI) is the sum of the percentages of participants reclassified correctly as cases and
controls.
* Significance: P  .05.
yP  .01.
zP  .001.
xP  .0001.
443Z.-Y. Zhang et al. / Journal of the American Society of Hypertension 12(6) (2018) 438–447
444 Z.-Y. Zhang et al. / Journal of the American Society of Hypertension 12(6) (2018) 438–447were consistently higher in the low compared with the
high-risk group, whereas the misclassification rate showed
the opposite trend (Table 2). In all and aged participants,
both IDI and NRI reached significance (P  .024), whereas
this was also the case for NRI in overweight, normal
weight, and normotensive people (P  .007).
Discussion
The objective of our present study was to evaluate
whether the multidimensional urinary biomarker HF1 could
discriminate over a 5-year horizon between normal LV
function and mildly impaired LVDD. The key findings
can be summarized as follows: (1) in continuous analyses,
lower e’ and greater E/e’ at follow-up were associated with
higher baseline HF1; (2) in categorical analyses, HF1 pre-
dicted subclinical LVDD and; (3) over a 5-years horizon,
HF1 improved discrimination between people with normal
and mildly impaired diastolic LV function. Two previous
FLEMENGHO reports25,27 illustrate the clinical relevance
of the early diagnosis of LVDD. Higher HF125 and lower
e’27 over a median follow-up of 5–6 years predicted the
incidence of cardiovascular complications. An unexpected
finding was that over this short follow-up period, HF1
was more predictive than systolic blood pressure.25 This
observation probably reflects the time course of events, sys-
tolic blood pressure being a major driver of LVDD. In the
Framingham Heart Study, remote blood pressure (average
of all reading 11–20 years before current) and recent blood
pressure (average of all readings 1–10 years before current)
predicted cardiovascular disease incrementally over current
blood pressure.28 Explanations offered by the Framingham
investigators were that antecedent blood pressure is a fore-
runner of cardiovascular target organ damage, which is on
the path to hard cardiovascular complications and that the
relation between cardiovascular risk and blood pressure
weakens over time, for instance by the initiation of antihy-
pertensive drug treatment.28
While the diagnosis of DHF remains challenging in a
hospital environment, this is even more the case for asymp-
tomatic LVDD at the point of entry in health care. Echocar-
diography is the diagnostic approach recommended by
guidelines, which requires highly skilled observers and is
costly and impossible to implement on a large scale. Hence,
screening by means of biomarkers in primary care is an op-
tion to be favored. Figure 3 proposes how HF1 might be
applied in clinical practice in asymptomatic high-risk indi-
viduals. In the presence of one or more clinical risk factors
for LVDD, in particular the combination of seniority, over-
weight or abdominal obesity, and hypertension (N ¼ 162;
25.1% of our study population), HF1 might be used as a
screening tool. If the value is < 0.350, managing risk fac-
tors over a 5-year time span is the intervention to be recom-
mended. In contrast, if HF1 is  0.350, a second test
might inform the health-care provider whether continuingmanaging risk factors for 5 years is sufficient or whether
the patient should be referred for echocardiography. An
added benefit is that HF1 predicts worsening of renal func-
tion24 and the 5-year incidence of cardiovascular and car-
diac events.25 NT-proBNP is the biomarker most
frequently used in clinical practice, but its distribution
shows large overlap between individuals with normal dia-
stolic LV function, LVDD, or even DHF.10,27 In our present
study, in line with previous publications,3,4,6 NT-proBNP
did not add to the prediction of LVDD over and beyond
classical risk factors. Moreover, HF1 in the presence of
NT-proBNP fully retained its prognostic value. Another
issue to be considered is the risk assessment of individuals
not at high risk. In such participants, HF1 values  0.350
tended to have higher sensitivity than in high-risk individ-
uals (Table 2). The large amount of prognostic information
carried by old age and higher BMI (Figures 1 and 2)
explain this observation. Thus, although a positive test in
low-risk individuals is predictive, it cannot be recommen-
ded, because its application on a large scale is
impracticable.
A major advantage of running proteomics on urine sam-
ples is the comfort for the patient because all what is
needed is a fresh mid-morning urine sample of 5 mL. Uri-
nary proteins remain stable for a time long enough to
perform the proteome analysis in a reliable manner.29
Two independent sets of experiments demonstrated that
the urinary proteome does not undergo significant changes
when urine is stored for 3 days at 4C30 or for 6 hours at
room temperature.31 Moreover, for studies running over
several years, urine can be stored at 20C without signif-
icant alteration of the proteome.29 The urinary proteome is
well characterized, and reference standards are available.8
CE-MS that provides sufficient sensitivity and high repro-
ducibility is capable to resolve up to 6000 different peptides
per sample within approximately 45 minutes.32 On the
other hand, urinary proteomic analysis remains substan-
tially more costly than other diagnostic tests employed in
the management of patients at risk of or already having
LVDD. However, a cost-effectiveness analysis within the
setting of the German health insurance system suggested
that CKD273, a multidimensional classifier used for the
early diagnosis of decline in the eGFR performs better
than microalbuminuria.33 Markov models were constructed
for diabetic patients free of chronic kidney disease or other
diabetic complication and assumed follow-up from 45 until
85 years or death. By using CKD273 instead of microalbu-
minuria, the overall cost per patient was V17,567 ($20,731)
lower, and the number of patients progressing to dialysis
decreased by 30%.33 Whether or not the Markov models
would materialize in clinical care is currently being tested
in a randomized clinical trial.34
Our current and previous findings are in line with the
pathophysiologic concepts underlying deterioration of dia-
stolic LV function. In patients with LVDD, the LV wall
Figure 3. Proposal for the clinical application of HF1 over a 5-year horizon, pending confirmation in an independent cohort, and ul-
timately testing in a proof-of-concept randomized clinical trial.
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deposition12 and cross-linking of collagen I at the detriment
of collagen III.13,14 Small increases in the collagen I/III ra-
tio augment myocardial stiffness, thereby reducing early
diastolic LV filling and increasing LV filling pressure.35,36
Of the peptides with known amino acid sequence, which
make up HF1, 60.0%9 consist of dysregulated collagen
fragments. Recent cross-sectional analyses of sequenced
urinary peptides in FLEMENGHO participants demon-
strated that LVDD was associated with higher levels of uri-
nary collagen I fragments, lower levels of urinary collagen
III degradation products, and higher levels of circulating
tissue inhibitor of matrix metalloproteinase type I, an inhib-
itor of collagen-degrading enzymes.11 Combined, these
data suggest that HF1 reflects collagen degradation, and
in this way reveals relevant molecular processes that subse-
quently lead to remodeling of the extracellular matrix and
fibrosis of the myocardium.
Strong points of our study are the assessment of Doppler
indexes as early signs of subclinical LVDD and the adjust-
ment of our analyses for a large number of covariables
measured simultaneously with the urinary biomarker.
What our study additionally highlighted is the strong age
dependency of both diastolic LV function and the HF1
marker and providing a justification for repeating the mea-
surement of HF1 if its value is  0.350, as is currently
recommended for albuminuria in the field of chronic kidneydisease.37 Of note, HF1 retained its prognostic significance
over and beyond established LVDD risk factors, in partic-
ular age and abdominal obesity. In all and older partici-
pants, HF1 improved both IDI and NRI. However, our
study must also be interpreted within the context of its lim-
itations. Although as outlined cardiovascular outcome
data25,27 add a perspective to our current observations, an
observational study cannot fully prove the utility of a
biomarker. Further validation of HF1 as screening tool in
a randomized clinical trial is therefore necessary. Such
approach is presently being implemented to validate
CKD27338 in the multicenter double-blind placebo-
controlled PRIORITY trial (proteomic prediction and
renin-angiotensin aldosterone system inhibition prevention
of early diabetic nephropathy in type II diabetic patients
with normal albumin excretion).34 Second, notwithstanding
the consistency of the association between LVDD and HF1
in a discovery and test case-control study9 and subsequently
in the general population10 and the pathophysiological
plausibility in mechanistic studies,11 replication in an inde-
pendent cohort would enhance the clinical relevance of our
findings. Third, a sensitivity ranging from 43.0% to 77.3%
might be considered as low. However, ECG is a commonly
used instrument with a sensitivity of only 35% to diagnose
echocardiographically confirmed LV hypertrophy.39
Finally, our present study cannot prove the cardiac origin
of the urinary collagen fragments that contribute to HF1.
446 Z.-Y. Zhang et al. / Journal of the American Society of Hypertension 12(6) (2018) 438–447However, in a tissue proteomic study,40 we applied liquid
chromatography-tandem mass spectrometry to analyze bi-
opsies from explanted human hearts, 15 with ischemic car-
diomyopathy, 14 with dilated cardiomyopathy, and 12
healthy donor hearts discarded from implantation (control).
In both ischemic and dilated cardiomyopathy, the tissue
proteomic signature consistently showed higher abundance
of proteins involved in the organization of the extracellular
matrix, which is in agreement with the contribution of dys-
regulated collagen fragments to HF1.41
In conclusion, in a general population, HF1 allows
screening for LVDD. Our current observations support the
concept of porting easily obtainable multidimensional uri-
nary biomarkers8 to clinical practice to enable a personal-
ized approach to the diagnosis, prevention, and treatment
of LVDD, a high-risk condition27 that affects 25% of the
general population.3,4 Such biomarkers might be particu-
larly useful in primary health care, particularly in older
high-risk patients with hypertension or abdominal obesity
and serve as a decision tool informing doctors when referral
for echocardiography is indicated.References
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Appendix
Expanded Methods
Participants collected 24-hour urine samples within 1
week of the clinical examination at the field center. Ali-
quots (0.7 mL) were stored at 80C and thawed immedi-
ately before analysis. To remove higher molecular mass
proteins, such as albumin and immunoglobulin G, the sam-
ples were ultrafiltered using Centrisart ultracentrifugation
devices (20 kDa MWCO; Sartorius, G€ottingen, Germany)
at 2000 g relative centrifugal force until 1.1 mL of filtrate
was obtained. This filtrate was then applied onto a PD-10
desalting column (GE Healthcare, Uppsala, Sweden) equil-
ibrated in 0.01% NH4OH in HPLC-grade H2O (Roth, Ger-
many) to decrease matrix effects by removing urea,
electrolytes, and salts and to enrich peptides. Finally, all
samples were lyophilized, stored at 4C, and suspended
in HPLC-grade H2O shortly before capillary electropho-
resis coupled with mass spectrometry (CE-MS).
As described in detail elsewhere,1–3 CE-MS analyses
were performed using a P/ACE MDQ capillary electropho-
resis system (Beckman Coulter, Brea, California, USA) on-
line coupled to a micrOTOF MS (Bruker Daltonic, Bremen,
Germany). The ESI sprayer (Agilent Technologies, Palo
Alto, CA, USA) was grounded, and the ion spray interface
potential was set between 4 and 4.5 kV. Data acquisition
and mass spectrometry acquisition methods were automat-
ically controlled by the capillary electrophoresis via
contact-close relays. Spectra were accumulated every 3 sec-
onds, over a range of charge states (m/z) 350–3000. Previ-
ous publications described the accuracy, precision,
selectivity, sensitivity, reproducibility, and stability of the
CE-MS measurements in detail.3,4 Mass spectra were pro-
cessed using MosaiquesVisu software, including peak pick-
ing, deconvolution, and de-isotoping.5 Migration time and
peak intensity were normalized, using internal polypeptide
standards.6 These fragments result from normal biological
processes and appear to be unaffected by any disease state
studied to date based on over 30,000 samples in the Mosai-
ques database.7 The resulting peak list characterizes each
polypeptide by its molecular mass, normalized capillary
electrophoresis migration time, and normalized signal in-
tensity. All detected polypeptides were deposited, matched,
and annotated in a Microsoft SQL database, allowing
further analysis and comparison of multiple patient groups.
For targeted sequencing, urine samples were analyzed on
a Dionex Ultimate 3000 RSLS nano flow system (Dionex,
Camberly, UK) or on a Beckman CE, interfaced with an
Orbitrap Velos MS instrument (Thermo Scientific, Wal-
tham, MA, USA).3 The data files were analyzed using Pro-
teome Discoverer 1.2 (precursor mass tolerance, 5 ppm;
fragment mass tolerance, 0.05 Da) and were searched
against the UniProt human nonredundant database without
enzyme specificity. No fixed modifications were selected.
Oxidation of methionine and proline were considered as
variable modifications. The criteria for accepting sequences
were high confidence (Xcorr 1.9) and absence of unmod-
ified cysteine. A strict correlation between peptide charge
at the working pH of two and capillary electrophoresis
migration time was used to avoid falsely characterized
peptides.8
Peptide fragments identified in previous study were com-
bined into a single summary variable, using the support-
vector machine based MosaCluster software, version
1.6.5. As published previously,9 HF1 combined information
from 85 peptide fragments identified in 19 patients with
diastolic LV dysfunction and 19 controls.
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Table S1
List of polypeptides included in the HF1 classifier
Polypeptide Cases Controls R P-value
(Unadjusted)
ID Mass (Da) CE Time (min) MA (%) MA (%)
81,272 2211.98 33.23 0 (0) 2.67 (0.42) 0 1.99E-03
12,9821 3333.36 19.42 0 (0) 2.39 (0.47) 0 8.72E-04
8725 949.4 25.79 1.94 (0.05) 2.28 (0.63) 0.067 2.22E-04
123,106 3130.43 30.82 1.98 (0.05) 2.63 (0.47) 0.080 2.57E-03
1577 840.41 23.17 1.65 (0.05) 1.85 (0.47) 0.095 3.29E-03
103,493 2658.22 19.5 3.36 (0.05) 3.29 (0.47) 0.109 4.71E-03
44,146 1518.6 19.37 1.91 (0.11) 2.49 (0.58) 0.145 1.33E-03
4845 900.27 43.66 1.55 (0.16) 2.44 (0.63) 0.161 1.33E-03
37,610 1421.59 38.71 1.73 (0.11) 1.87 (0.53) 0.192 6.07E-03
83,441 2248.97 33.69 3.45 (0.11) 3.56 (0.53) 0.201 4.88E-03
74,703 2087.84 19.42 2.64 (0.11) 2.7 (0.53) 0.203 6.76E-03
101,157 2616.16 28.39 197 (0.11) 1.98 (0.53) 0.206 6.76E-03
103,022 2649.2 34.85 2.52 (0.16) 2.56 (0.68) 0.232 2.50E-03
57,360 1734.66 19.9 2.2 (0.16) 2.24 (0.58) 0.271 1.03E-02
46,091 1554.66 28.59 2.08 (0.16) 2.24 (0.53) 0.280 1.18E-02
32,022 1319.58 20.89 1.99 (0.21) 2.21 (0.58) 0.326 1.57E-02
102,269 2638.18 28.42 2.3 (0.26) 2.49 (0.68) 0.353 1.26E-02
82,708 2235.04 34.17 2.57 (0.32) 2.68 (0.84) 0.365 2.53E-03
188,895 11,967.55 20.47 2.68 (0.26) 2.94 (0.63) 0.376 9.50E-03
98,089 2559.18 19.41 2.97 (0.32) 3 (0.84) 0.377 3.76E-03
138143 3593.47 20.2 2.67 (0.26) 2.68 (0.68) 0.381 1.50E-02
167,786 4771.07 20.2 2.74 (0.37) 3.13 (0.79) 0.410 4.34E-03
61,984 1835.71 19.91 2.64 (0.53) 3.12 (1) 0.448 1.33E-04
46,369 1560.7 29.79 2.78 (0.32) 2.84 (0.68) 0.461 2.27E-02
143,947 3801.77 33.46 2.26 (0.37) 2.24 (0.79) 0.473 2.67E-02
39,275 1445.62 37.36 2.59 (0.47) 2.96 (0.79) 0.521 4.87E-03
56,493 1716.66 20.18 2.56 (0.47) 2.74 (0.79) 0.556 2.11E-02
41,972 1478.61 39.3 2.75 (0.53) 2.95 (0.84) 0.588 3.16E-03
24,168 1195.48 37.51 2.8 (0.58) 3.26 (0.84) 0.593 3.12E-03
107,858 2751.34 29.23 2.36 (0.63) 2.69 (0.89) 0.621 3.00E-03
23,356 1179.52 37.49 2.63 (0.58) 2.9 (0.84) 0.626 2.67E-02
97,599 2547.99 21.44 2.59 (0.58) 2.66 (0.89) 0.635 3.15E-02
8695 949.22 34.33 2.46 (0.53) 3.01 (0.68) 0.637 2.78E-02
23,697 1186.53 22.39 2.8 (0.68) 2.88 (1) 0.661 2.08E-02
36,566 1401.38 36.56 2.77 (0.58) 3.27 (0.74) 0.664 8.74E-03
153,832 4196.75 20.84 2.41 (0.68) 2.59 (0.95) 0.666 4.93E-03
26,670 1235.56 26.65 3.02 (0.63) 3.3 (0.84) 0.686 1.08E-02
58,050 1749.81 30.61 2.57 (0.63) 2.79 (0.84) 0.691 3.04E-02
28,005 1255.48 35.77 3.08 (0.68) 3.4 (0.84) 0.733 3.19E-02
159,396 4409.89 20 2.72 (0.74) 3.23 (0.84) 0.742 2.68E-02
69,979 1996.79 20.98 2.86 (0.79) 3.17 (0.95) 0.750 8.53E-03
40,737 1462.62 39.42 3.33 (0.84) 3.68 (1) 0.760 2.62E-04
65,368 1901.82 43.83 3.17 (0.79) 3.61 (0.89) 0.779 1.52E-02
128,086 3286.55 30.92 3.13 (0.79) 3.51 (0.89) 0.792 6.91E-04
73,434 2067.82 20.62 3.1 (0.84) 3.28 (1) 0.794 1.42E-02
148,086 3986.65 20.6 3.53 (0.84) 3.82 (0.95) 0.817 2.75E-03
108,574 2764.21 42.63 3.56 (0.79) 3.85 (0.89) 0.821 2.43E-02
90,344 2377.1 20.8 3.12 (0.89) 3.46 (0.95) 0.845 1.95E-02
36,759 1405.61 39.04 2.94 (0.89) 3.18 (0.95) 0.866 1.02E-02
147,541 3968.6 21.09 3.14 (0.89) 3.57 (0.89) 0.880 1.77E-03
28,561 1265.59 27.09 3.36 (0.89) 3.79 (0.89) 0.887 1.10E-02
107,460 2742.25 28.98 2.91 (0.95) 3.11 (1) 0.889 1.19E-02
32,171 1321.59 28.37 4.07 (0.95) 4.27 (1) 0.906 1.82E-02
(continued on next page)
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Table S1 (continued )
Polypeptide Cases Controls R P-value
(Unadjusted)
ID Mass (Da) CE Time (min) MA (%) MA (%)
39,322 1446.64 39.43 3.2 (1) 3.49 (1) 0.917 3.19E-02
35,339 1378.61 28.82 3.36 (1) 3.53 (1) 0.952 1.54E-02
81,196 2210.95 33.61 3.72 (1) 13.59 () 1.036 2.15E-02
41,601 1469.67 23.69 3.72 (1) 3.56 (1) 1.045 2.33E-02
62,866 1854.81 40.92 3.89 (1) 3.71 (1) 1.048 1.98E-02
99,021 2570.19 42.56 3.88 (1) 3.7 (1) 1.049 1.19E-02
79,136 2175 33.28 3.74 (1) 3.49 (1) 1.072 1.09E-02
50,840 1623.73 24.12 4.17 (0.95) 3.86 (0.95) 1.080 9.77E-03
72,533 2046.92 32.58 3.49 (0.95) 3.21 (0.95) 1.087 1.06E-02
57,537 1737.78 23.73 4.02 (1) 3.82 (0.95) 1.108 2.15E-02
50,212 1613.82 23.99 2.7 (0.89) 2.43 (0.89) 1.111 3.30E-02
60,149 1794.8 23.92 3.72 (1) 3.47 (0.95) 1.128 6.20E-03
103,198 2654.19 23.92 2.94 (0.89) 2.47 (0.89) 1.190 5.52E-03
104,786 2679.2 23.53 3.58 (1) 3.34 (0.89) 1.204 7.89E-03
33,135 1338.6 23.99 2.86 (1) 2.65 (0.89) 1.213 1.20E-02
73,291 2064.92 24.46 2.75 (0.84) 2.37 (0.79) 1.234 3.25E-02
45,021 1532.62 26.35 2.82 (1) 2.55 (0.89) 1.243 1.67E-02
99,475 2577.25 24.67 2.78 (0.95) 0.892.38 () 1.247 6.05E-03
40,294 1452.66 23.61 2.85 (1) 0.842.62 () 1.295 2.17E-03
35,424 1380.64 23.83 2.79 (0.95) 0.792.56 () 1.311 7.17E-03
131,294 3375.57 31.92 2.87 (1) 2.71 (0.79) 1.341 1.80E-02
111,564 2841.26 24.54 3.21 (0.89) 2.67 (0.79) 1.354 4.98E-03
104,195 2663.2 23.51 2.61 (0.89) 2.29 (0.74) 1.371 2.07E-02
28,747 1268.57 27.25 3.44 (1) 3.32 (0.74) 1.400 1.01E-02
44,802 1526.69 23.92 2.51 (0.79) 2.1 (0.63) 1.499 1.10E-02
113,452 2889.35 24.08 2.47 (0.89) 2.29 (0.58) 1.655 7.34E-03
69,681 1989.88 32.44 2.43 (0.84) 2.51 (0.42) 1.936 2.03E-02
55,516 1696.72 23.95 2.54 (0.79) 2.39 (0.42) 1.999 1.59E-02
80,360 2196.02 33.16 2.74 (0.68) 2.73 (0.26) 2.625 1.15E-02
82,784 2236.98 27.14 2.28 (0.63) 2.31 (0.21) 2.961 1.29E-02
56,806 1723.52 37.74 2.31 (0.53) 2.52 (0.11) 4.417 1.03E-02
129,182 3320.51 24.25 2.07 (0.47) 2.1 (0.05) 9.266 4.71E-03
ID, polypeptide identifier (SQL number); %, percentage of samples, in which the polypeptide could be detected; MA, mean signal ampli-
tude of the polypeptides.
R was calculated as
P
(ln signal amplitude  frequency/number of participants) in controls divided byP (ln signal amplitude  fre-
quency/number of participants) in cases. The polypeptides were ordered by ascending R. Published under CC BY-NC-ND license.
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Table S2
Echocardiographic measurements by quartiles of the HF1 distribution
Characteristic Categories of the Urinary HF1 Biomarker
Limits, Score <1.623 1.623 to 1.047 1.046 to 0.445 >0.445
Conventional
echocardiography
Left atrial volume
index, mL/m2
24.6  5.46 26.2  6.79* 26.2  7.32 27.5  7.22
Left ventricular
mass index, g/m2
89.6  16.7 97.0  21.4z 96.6  21.2 104.3  24.1y
Doppler data
E peak, cm/s 70.8  14.8 68.6  15.8 65.9  15.4 62.1  15.0*
A peak, cm/s 56.4  13.8 60.6  15.9* 62.2  14.5 65.5  15.7
E/A ratio 1.35  0.50 1.21  0.44* 1.12  0.40 1.01  0.40*
e0 peak, cm/s 11.4  3.26 10.0  3.44z 9.40  2.98 8.14  3.11z
a0 peak, cm/s 9.08  2.02 9.66  2.06* 9.75  2.32 9.77  2.03
e0/a0 ratio 1.40  0.71 1.14  0.59z 1.07  0.55 0.90  0.45y
E/e0 ratio 6.56  1.81 7.44  2.79z 7.44  2.06 8.36  3.00y
* Significance of the difference with the adjacent lower quartile: P  .05.
yP  .01.
zP  .001.
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